Kringle Pharma, Inc.

TSE:4884 주식 보고서

시가총액: JP¥5.6b

Kringle Pharma 과거 수익 실적

과거 기준 확인 0/6

Kringle Pharma's earnings have been declining at an average annual rate of -33.4%, while the Biotechs industry saw earnings growing at 10.5% annually. Revenues have been declining at an average rate of 12.8% per year.

주요 정보

-33.4%

수익 성장률

64.5%

EPS 성장률

Biotechs 산업 성장31.9%
매출 성장률-12.8%
자기자본 수익률-33.9%
순이익-1,005.2%
다음 실적 업데이트13 Nov 2024

최근 과거 실적 업데이트

Recent updates

Here's Why We're Not Too Worried About Kringle Pharma's (TSE:4884) Cash Burn Situation

Jun 15
Here's Why We're Not Too Worried About Kringle Pharma's (TSE:4884) Cash Burn Situation

We Think Kringle Pharma (TSE:4884) Can Afford To Drive Business Growth

Mar 02
We Think Kringle Pharma (TSE:4884) Can Afford To Drive Business Growth

수익 및 비용 분석

Kringle Pharma 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.


수익 및 매출 내역

TSE:4884 수익, 비용 및 수입 (JPY Millions )
날짜수익수익G+A 비용R&D 비용
30 Jun 2479-794211716
31 Mar 2478-905302716
31 Dec 2370-866255716
30 Sep 2369-854242716
30 Jun 23330-603373533
31 Mar 23398-327207533
31 Dec 22395-359237533
30 Sep 22391-331196533
30 Jun 22284-361251398
31 Mar 22199-428229398
31 Dec 21208-368172398
30 Sep 21289-301178398
30 Jun 21523-196288489
30 Sep 20467-117150489
30 Sep 190-3023710

양질의 수익: 4884 is currently unprofitable.

이익 마진 증가: 4884 is currently unprofitable.


잉여현금흐름 대 수익 분석


과거 수익 성장 분석

수익추이: 4884 is unprofitable, and losses have increased over the past 5 years at a rate of 33.4% per year.

성장 가속화: Unable to compare 4884's earnings growth over the past year to its 5-year average as it is currently unprofitable

수익 대 산업: 4884 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4%).


자기자본 수익률

높은 ROE: 4884 has a negative Return on Equity (-33.91%), as it is currently unprofitable.


자산 수익률


고용 자본 수익률


과거 성과가 우수한 기업 찾기